5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique
Gregg W Stone,Dean J Kereiakes,Tommaso Gori,D Christopher Metzger,Bernardo Stein,Matthew Erickson,Jan Torzewski,Ameer Kabour,Guy Piegari,Jeffrey Cavendish,Barry Bertolet,Kelly A Stockelman,Nick E J West,Ori Ben-Yehuda,James W Choi,Steven O Marx,John A Spertus,Stephen G Ellis,ABSORB IV Investigators
DOI: https://doi.org/10.1016/j.jacc.2023.05.003
2023-07-18
Abstract:Background: Bioresorbable vascular scaffolds (BVS) were designed to improve late event-free survival compared with metallic drug-eluting stents. However, initial trials demonstrated worse early outcomes with BVS, in part due to suboptimal technique. In the large-scale, blinded ABSORB IV trial, polymeric everolimus-eluting BVS implanted with improved technique demonstrated noninferior 1-year outcomes compared with cobalt chromium everolimus-eluting stents (CoCr-EES). Objectives: This study sought to evaluate the long-term outcomes from the ABSORB IV trial. Methods: We randomized 2,604 patients at 147 sites with stable or acute coronary syndromes to BVS with improved technique vs CoCr-EES. Patients, clinical assessors, and event adjudicators were blinded to randomization. Five-year follow-up was completed. Results: Target lesion failure at 5 years occurred in 216 (17.5%) patients assigned to BVS and 180 (14.5%) patients assigned to CoCr-EES (P = 0.03). Device thrombosis within 5 years occurred in 21 (1.7%) BVS and 13 (1.1%) CoCr-EES patients (P = 0.15). Event rates were slightly greater with BVS than CoCr-EES through 3-year follow-up and were similar between 3 and 5 years. Angina, also centrally adjudicated, recurred within 5 years in 659 patients (cumulative rate 53.0%) assigned to BVS and 674 (53.3%) patients assigned to CoCr-EES (P = 0.63). Conclusions: In this large-scale, blinded randomized trial, despite the improved implantation technique, the absolute 5-year rate of target lesion failure was 3% greater after BVS compared with CoCr-EES. The risk period for increased events was limited to 3 years, the time point of complete scaffold bioresorption; event rates were similar thereafter. Angina recurrence after intervention was frequent during 5-year follow-up but was comparable with both devices.(Absorb IV Randomized Controlled Trial; NCT02173379).